x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

business

All Episodes

32:40

390: FDA turmoil, election intrigue, AI, and more

The Readout Loud ·

2026/02/26

On "The Readout LOUD" this week: Adam Feuerstein, solo. His usual co-hosts Allison DeAngelis and Elaine Chen took some time off, so Adam manned the podcast mic himself.Adam thought, quite understandably, that our cherished listeners wouldn’t want to hear him drone on for 30 minutes, so he thankfully found some help. Jared Holz, health care sector specialist at Mizuho Securities, agreed to be Adam’s podcasting wingman for this week’s show.They ran through a menu of takes on biotech stock

en

34:20

389: Hims' Super Bowl fallout, and the FDA reverses...

The Readout Loud ·

2026/02/19

Was Hims' Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what's happening behind-the-scenes with Moderna and the Food and Drug Administration?We discuss all that on this week's episode of "The Readout LOUD." STAT's Katie Palmer joins Adam, Elaine, and Allison to discuss the Hims GLP-1 pill fallout. The hosts also discuss the latest on Moderna's influenza vaccine application and Compass Pathways' depression psychedelic data.

en

51:24

388: The FDA's refusal to review Moderna's mRNA flu...

The Readout Loud ·

2026/02/12

We’re devoting our entire episode this week to one controversial and impactful topic: the FDA’s decision to block the review of Moderna’s mRNA flu shot.STAT was the first to report that Vinay Prasad, the agency’s top regulator of vaccines, overruled the head of the FDA’s vaccine office and other staffers in making that decision. Prasad’s unilateral action has renewed concerns about the FDA’s regulatory posture under the Trump administration. To help us dig deeply into this important story and its

en

28:04

387: Challenges for a crucial sickle cell treatment...

The Readout Loud ·

2026/02/05

On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment.It’s our pre-Super Bowl show, which triggered some co-host squabbling. Adam Feuerstein is all Patriots, Elaine Chen is Team Seahawks, while Allison DeAngelis, raised in Seattle but

en

61:36

From Drug Story: Lipitor and Heart Disease

The Readout Loud ·

2026/02/03

This is an episode of Drug Story, a podcast by Thomas Goetz. You can find the rest of the series at https://www.drugstory.co/podcastOnce you turn 40, it seems like half the people you know are taking a statin drug. You know, because their cholesterol is high, and to prevent heart disease down the line. It makes sense: better safe than sorry. This is a huge triumph for preventive medicine. Statin drugs have saved (or improved) the lives of millions of people because they acted early. This is how

en

41:39

386: The high stakes for Huntington's patients

The Readout Loud ·

2026/01/29

Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington's disease, and the outcome could be potentially devastating for patients.That's what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Holder joins the podcast for an in-depth discussion of how the regulator's changing perspective on UniQure's trial affects patients, and patients' attempts to

en

29:47

385: A measles outbreak and hospitals' financial...

The Readout Loud ·

2026/01/22

Why is the U.S. at risk of losing its measles elimination status? How are health officials reacting to the measles outbreak? And what did top Centers for Medicare and Medicaid Services official Mehmet Oz tell hospital executives at a fancy yacht party in San Francisco?We discuss all that and more on this week's episode of "The Readout LOUD," STAT's weekly biotech podcast. We bring on our infectious disease reporter Helen Branswell to talk about the ongoing measles outbreak in South Carolina and

en

68:10

384: Live from the JP Morgan conference, a sit-down...

The Readout Loud ·

2026/01/14

For this very special episode of The Readout LOUD Allison, Adam, and Elaine are live from the J.P. Morgan Healthcare Conference in San Francisco.The hosts are joined by ARCH Venture Partners co-founder and managing director Bob Nelsen and new Novo Nordisk CEO Mike Doustdar joins the podcast hosts live to discuss his first few months on the job and the company's push to regain market share in the competitive obesity market.

en

33:35

383: JPM to bring more deals and happy CEOs

The Readout Loud ·

2026/01/08

What news happened over the holidays? Why will pharma CEOs be greeted warmly in San Francisco next week? And who will buy Revolution Medicines?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. We bring on former co-host Damian Garde, who’s now a reporter at large at STAT, to preview the upcoming J.P. Morgan Healthcare Conference. We also discuss the approval of Novo Nordisk’s Wegovy pill, the federal government’s move to slash the number of

en

34:07

382: Biotech's year in review

The Readout Loud ·

2025/12/18

Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays?We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at venture capital firm Atlas Venture, to reflect on everything that's happened in the biotech industry this year and to look ahead at the trends next year.We also chat about Adam's picks for best and worst

en

33:26

381: The future of American science and a dispatch...

The Readout Loud ·

2025/12/11

How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of Health?First, we discuss all things ASH, particularly Tern’s chronic myeloid leukemia data, Johnson & Johnson’s multiple myeloma data, and Fulcrum Therapeutics’ pill for sickle cell disease. We also get into the latest

en

32:45

380: A new top drug regulator and the future of...

The Readout Loud ·

2025/12/04

On this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news.Our special guest this week is David Olson, director of the UC Davis Institute for Psychedelics and Neurotherapeutics and the co-founder of Delix Therapeutics, a startup that is developing a new class of neuropsychiatric medicines that are similar to

en

37:10

379: How Mark Cuban plans to ‘f— up’ health care

The Readout Loud ·

2025/11/20

How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible program ever”? And what are his thoughts on sports betting?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Cuban comes on for an extensive chat about the latest biosimilar launch by his company, Cost Plus Drugs, as well his broader thoughts on

en

36:06

378: Merck's heart disease win and the FDA's new drug...

The Readout Loud ·

2025/11/13

What does Rick Pazdur's new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices?Dean Li, the head of R&D at Merck, joins us to discuss the long-awaited trial results for the company's oral medicine targeting PCSK9 to lower cholesterol. These types of treatments have proven effective at addressing heart disease, but making them into more accessible pills has proven tricky.We also discuss

en

31:21

377: Melodrama at the FDA and the Pfizer-Novo bidding...

The Readout Loud ·

2025/11/06

On a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence about a slow-boiling feud between Vinay Prasad, the head of the FDA’s biologics and vaccine branch, and his staff that has triggered even more exits and plunging morale.On the drug side of the agency, we dish on the shocking exit of director George Tidmarsh after he was accused of using his regulatory position to exact personal revenge against a former business partner

en

38:12

376: BridgeBio’s great week and Moderna’s unraveling

The Readout Loud ·

2025/10/30

Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween?We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the company’s positive Phase 3 readouts and our colleague Jason Mast to discuss Moderna’s struggles following its Covid-19 vaccine boom.

en

29:12

375: Startups push the FDA and biotech booms in North...

The Readout Loud ·

2025/10/23

Can Trump take credit for North Carolina's booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the STAT Summit?We discuss all that and more in the latest episode of "The Readout LOUD."Elaine is out this week, so Adam and Allison dive into the latest news in the life science industry together, including the two companies pushing the Food and Drug Administration, the first recipients of the Commissioner’s National Priority Review voucher, and why

en

34:10

374: Veteran biotech executive Clive Meanwell on drug...

The Readout Loud ·

2025/10/16

On this week’s episode of “The Readout LOUD”: an interview with veteran biotech executive and company founder Clive Meanwell. Pfizer recently acquired one of Meanwell’s companies, the obesity drug developer Metsera, for just under $5 billion.Meanwell offered his perspectives on the evolving obesity drug market, and continued need for drugs to treat diseases with large prevalence, which he’s doing with his latest venture, called Corsera Health. Meanwell also weighed in on drug pricing policies both

en

45:40

373: Party in biotech land and AstraZeneca’s...

The Readout Loud ·

2025/10/09

Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back?We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care strategist Jared Holz to discuss the rebound in biotech stocks and sentiment. We also talk about Marks’ new role at Eli Lilly after leaving the Food and Drug Administration, an attempt by a biotech to revive a rare disease drug

en

28:05

372: A pharma C-suite shakeup and Trump's deal with...

The Readout Loud ·

2025/10/02

How will we look back on Emma Walmsley's tenure as GSK's CEO? Why did one of the FDA's top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff?Adam is out this week, so Allison and Elaine dive into the latest news, starting with another biotech acquisition and a new CEO at GSK. Then, they invite health policy researcher Stacie Dusetzina to break down President Trump's "most-favored nation" pricing deal with Pfizer.

en

395 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...